Péptidos inhibidores del PSMA radiomarcados para el estudio del carcinoma de próstata
Barra lateral del artículo
Publicado:
jun 1, 2021
Palabras clave:
tomografía de emisión computerizada de fotón único, tomografía computerizada con positrón, neoplasmas, próstata, antígenos, inhibición, marcado
Contenido principal del artículo
Resumen
El cáncer de próstata, con una elevada incidencia y como segunda causa de muerte en la población masculina, constituye un serio problema de salud, que se agrava con los años. El diagnóstico temprano y el correcto estadío de esta enfermedad son importantes para el adecuado manejo del paciente. En este sentido, la imagen molecular con técnicas de Medicina Nuclear resulta de gran utilidad, por lo que el desarrollo de nuevas moléculas peptidomiméticas con afinidad por receptores de membrana, que se sobrexpresen en el cáncer de próstata, como el antígeno prostático específico (PSMA), ha permitido dar un salto cualitativo en la detección temprana y seguimiento del carcinoma prostático. El presente trabajo está dirigido a brindar una panorámica del estado de los péptidos inhibidores del PSMA, derivados de la secuencia -Lys-Urea-Glu-, como radiofármacos para el estudio de las neoplasias de próstata, que hoy día se encuentran en diferentes fases de desarrollo, mostrando, de forma general, una elevada especificidad, adecuada captación en el tejido tumoral y satisfactoria farmacocinética, para ser empleados en el estudio del cáncer de próstata, tanto mediante tomografía por emisión de positrones (PET), como por medio de tomografía por emisión de fotón único (SPECT).
Detalles del artículo
Cómo citar
Perera Pintado, A., Prats Capote, A., & Cruz Arencibia, J. (2021). Péptidos inhibidores del PSMA radiomarcados para el estudio del carcinoma de próstata. Nucleus, (68). Recuperado a partir de http://nucleus.cubaenergia.cu/index.php/nucleus/article/view/711
Número
Sección
Ciencias Nucleares
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. Bajo esta licencia el autor será libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y crear a partir del material
- El licenciador no puede revocar estas libertades mientras cumpla con los términos de la licencia
Bajo las siguientes condiciones:
- Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
- NoComercial — No puede utilizar el material para una finalidad comercial.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
La Revista Nucleus solo aceptará contribuciones que no hayan sido previamente publicados y/o procesados, por otra publicación. Cualquier violación ese sentido será considerada una falta grave por parte del autor principal lo cual será objeto valoración por parte del Consejo Editorial, el cual dictaminará al respecto.
Citas
[1]. TEOH JYC, HIRAI HW, HO JMW, CHAN FCH, et al. Global incidence of prostate cancer in developing and developed countries with changing age structures. PLoS ONE. 2019; 14(10): e0221775.
[2]. Ministerio de Salud Pública (MINSAP). Anuario estadístico de salud. Dirección de Registros Médicos y Estadísticas de Salud. MINSAP, 2020. ISSN: versión electrónica 1561-4433.
[3]. PILLAI MRA, NANABALA R, JOY A, SASIKUMAR A, et. al. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: effective theranostic tools for imaging and therapy of prostate cancer. Nucl Med Biol. 2016; 43(11): 692-720. doi: 10.1016/j.nucmedbio.2016.08.006.
[4]. RAWLA P. Epidemiology of prostate cancer. World J Oncol. 2019; 10(2): 63-89.
[5]. HABERKORN U, EDER M, KOPKA K, BABICH JW, et. al. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016; 22: 9-15.
[6]. BANERJEE SR, FOSS CA, CASTANARES M, MEASE RC, et. al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008; 51: 4504-4517.
[7]. LIU J, CHEN Z, WANG T, LIU L, et. al. Influence of four radiotracers in PET/CT on diagnostic accuracy for prostate cancer: a bivariate random-effects meta-analysis. Cell Physiol Biochem. 2016; 39: 467-480.
[8]. BALLAS LK, ABREU ALC, QUINN DI. What medical, urologic, radiation oncologists want from molecular imaging of prostate cancer. J Nucl Med. 2016; 57: 6S-12S.
[9]. LENZO NP, MEYRICK D, HARVEY TURNER J. Review of gallium-68 PSMA PET/CT imaging in the management of prostate cancer. Diagnostics. 2018; 8: 16. doi: 10.3390/diagnostics8010016.
[10]. SU H, ZHU Y, LING G, HU S, et. al. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse. Asian J Androl. 2017; 19: 267-271.
[11]. JADVAR H. PET glucose metabolism and cellular proliferation in prostate cancer. J Nucl Med. 2016; 57: 25S-29S.
[12]. MAPELLI P, INCERTI E, CECI F, CASTELLUCCI P, et. al. 11C- or 18F-Choline PET/CT for imaging evaluation of biochemical recurrence of prostate cancer. J Nucl Med. 2016; 57: 43S-48S.
[13]. CECI F, CASTELLUCCI P, MAPELLI P, INCERTI E, et. al. Evaluation of prostate cancer with 11C-choline PET/CT for treatment planning, response assessment, and prognosis. J Nucl Med 2016; 57: 49S-54S.
[14]. KOPKA K, BENESOVA M, BARINKA C, HABERKORN U, et. al. Glu-Ureido–based inhibitors of prostate-specific membrane antigen: lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers. J Nucl Med. 2017; 58: 17S-26S.
[15]. RAHBAR K, AFSHAR-OROMIEH A, JADVAR H, AHMADZADEHFAR H. PSMA theranostics: current status and future directions. Mol Imaging. 2018; 17: 1-9. doi: 10.1177/1536012118776068
[16]. GOURNI E, HENRIKSEN G. Metal-Based PSMA radioligands. Molecules. 2017; 22: 523. doi:10.3390/molecules22040523
[17]. EVANS JC, MALHOTRA M, CRYAN JF, O’DRISCOLL CM. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. British J Pharm. 2016; 173: 3041-3079.
[18]. BOSCHI A, UCCELLI L, MARTINI P. A picture of modern Tc-99m radiopharmaceuticals: production, chemistry, and applications in molecular imaging. Appl Sci. 2019; 9, 2526. doi: 10.3390/app9122526.
[19]. PANDIT-TASKAR N, VEACH DR, FOX JJ, SCHER HI, et. al. Evaluation of castration-resistant prostate cancer with androgen receptor-axis imaging. J Nucl Med. 2016; 57: 73S-78S.
[20]. WU M, SHU J. Multimodal molecular imaging: current status and future directions. Contrast Media Mol Imaging. 2018: 1382183. doi: 10.1155/2018/1382183.
[21]. OLIVA GONZÁLEZ JP, MARTÍNEZ RAMÍREZ A. Baum RP. Aplicaciones del PET/CT en oncología. Nucleus. 2017; (62): 10-12.
[22]. IAEA. Cyclotron produced radionuclides: physical characteristics and production methods. Technical Reports Series No. 468. Vienna: IAEA, 2009.
[23]. VIRGOLINI I, DECRISTOFORO C, HAUG A, FANTI S, et. al. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018; 45: 471-495.
[24]. CZARNIECKI M, MENA E, LINDENBERG L, CACKO M, et. al. Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents. Transl Androl Urol. 2018; 7(5): 831-843.
[25]. KLEIN NULENT TJW, van ES RJJ, KRIJGER GC, de BREE R, et. al. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma - a preliminary analysis. Eur J Nucl Med Mol Imaging. 2017; 44: 1614-1621.
[26]. GOURNI E, DEL POZZO L, BARTHOLOMA M, KIEFER Y, et. al. Radiochemistry and preclinical pet imaging of 68Ga-desferrioxamine radiotracers targeting prostate-specific membrane antigen. Mol Imaging. 2017; 16: 1-11. doi: 10.1177/1536012117737010
[27]. FENDLER WP, EIBER M, BEHESHTI M, BOMANJI J, et. al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017. doi 10.1007/s00259-017-3670-z
[28]. YOUNG JD, ABBATE V, IMBERTI C, MESZAROS LK, et. al. 68Ga-THP-PSMA: a PET imaging agent for prostate cancer offering rapid, room temperature, one-step kit-based radiolabeling. J Nucl Med. 2017; 58: 1270–1277.
[29]. PASTORINO S, RIONDATO M, UCCELLI L, GIOVACCHINI G, et. al. Toward the discovery and development of PSMA targeted inhibitors for nuclear medicine applications. Curr Radiopharm. 2020; 13: 63-79.
[30]. GIESEL FL, KNORR K, SPOHN F, WILL L, et. al. Detection efficacy of 18F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med. 2019; 60: 362-368.
[31]. CLEEREN F, LECINANJ, BILLAUD EMF, AHAMED M, et. al. New chelators for low temperature Al18F‑labeling of biomolecules. Bioconjugate Chem. 2016; 27; 790-798.
[32]. GIGLIO J, ZENI M, SAVIO E, ENGLER H. Synthesis of an Al18F radiofluorinated GLUUREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform. EJNMMI Radiopharm Chem. 2018; 3: 4. doi: 10.1186/s41181-018-0039-y.
[33]. HASSAN H, RAZAK HRA, SAAD FFA, KUMAR V. 18F[AlF]-radiolabelled peptides on the automated synthesis platform: translating the laboratory bench work to bedside. Malays J Med Sci. 2019; 26: 122-126.
[34]. CUI C, HANYU M, HATORI A, ZHANG Y, et. al. Synthesis and evaluation of [64Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer. Am J Nucl Med Mol Imaging. 2017; 7: 40-52.
[35]. MÜLLER C, DOMNANICH KA, UMBRICHT CA, van der MEULEN NP. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application. Br J Radiol. 2018; 91: 20180074.
[36]. PEDERSEN KS, BAUN C, NIELSEN KM, THISGAARD H, et. al. Design, synthesis, computational, and preclinical evaluation of natTi/45Ti-labeled urea-based glutamate PSMA ligand. Molecules 2020; 25: 1104. DOI:10.3390/molecules25051104
[37]. PERERA PINTADO A, TORRES AROCHE LA, VERGARA GIL A, BATISTA CUÉLLAR JF, et. al. SPECT/CT: principales aplicaciones en la medicina nuclear. Nucleus. 2017; (62): 2-9.
[38]. BARRETT JA, COLEMAN E, GOLDSMITH SJ, VALLABHAJOSULA S, et. al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013; 54: 380-387.
[39]. BANERJEE RS, PULLAMBHATLA M, FOSS CA, FALK A, et. al. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). J Med Chem. 2013; 56: 6108-6121.
[40]. FERRO-FLORES G, LUNA-GUTIÉRREZ M, OCAMPO-GARCÍA B, et al. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT. Nucl Med Biol. 2017; 48: 36-44.
[41]. XU X, ZHANG J, HU S, et. al. 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen. Nucl Med Biol. 2017; 48: 69-75.
[42]. ROBU S, SCHOTTELIUS M, EIBER M, et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med. 2017; 58: 235-242.
[43]. HENDRIKX JJMA. Automated synthesis and quality control of [99mTc]Tc-PSMA for radioguided surgery (in a [68Ga]Ga-PSMA workflow). EJNMMI Radiopharm Chem 2020; 5: 10. doi: 10.1186/s41181-020-00095-9.
[44]. WERNER P, NEUMANN C, EIBER M, WESTER HJ, SCHOTTELIUS M. [99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. EJNMMI Res. 2020; 10: 45. doi: 10.1186/s13550-020-00635-z.
[45]. VATS K, AGRAWAL K, SHARMA R, SARMA HD, SATPATI D, DASHAD A. Preparation and clinical translation of 99mTc-PSMA-11 for SPECT imaging of prostate cancer. Med Chem Commun. 2019; 10: 2111-2117.
[2]. Ministerio de Salud Pública (MINSAP). Anuario estadístico de salud. Dirección de Registros Médicos y Estadísticas de Salud. MINSAP, 2020. ISSN: versión electrónica 1561-4433.
[3]. PILLAI MRA, NANABALA R, JOY A, SASIKUMAR A, et. al. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: effective theranostic tools for imaging and therapy of prostate cancer. Nucl Med Biol. 2016; 43(11): 692-720. doi: 10.1016/j.nucmedbio.2016.08.006.
[4]. RAWLA P. Epidemiology of prostate cancer. World J Oncol. 2019; 10(2): 63-89.
[5]. HABERKORN U, EDER M, KOPKA K, BABICH JW, et. al. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016; 22: 9-15.
[6]. BANERJEE SR, FOSS CA, CASTANARES M, MEASE RC, et. al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008; 51: 4504-4517.
[7]. LIU J, CHEN Z, WANG T, LIU L, et. al. Influence of four radiotracers in PET/CT on diagnostic accuracy for prostate cancer: a bivariate random-effects meta-analysis. Cell Physiol Biochem. 2016; 39: 467-480.
[8]. BALLAS LK, ABREU ALC, QUINN DI. What medical, urologic, radiation oncologists want from molecular imaging of prostate cancer. J Nucl Med. 2016; 57: 6S-12S.
[9]. LENZO NP, MEYRICK D, HARVEY TURNER J. Review of gallium-68 PSMA PET/CT imaging in the management of prostate cancer. Diagnostics. 2018; 8: 16. doi: 10.3390/diagnostics8010016.
[10]. SU H, ZHU Y, LING G, HU S, et. al. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse. Asian J Androl. 2017; 19: 267-271.
[11]. JADVAR H. PET glucose metabolism and cellular proliferation in prostate cancer. J Nucl Med. 2016; 57: 25S-29S.
[12]. MAPELLI P, INCERTI E, CECI F, CASTELLUCCI P, et. al. 11C- or 18F-Choline PET/CT for imaging evaluation of biochemical recurrence of prostate cancer. J Nucl Med. 2016; 57: 43S-48S.
[13]. CECI F, CASTELLUCCI P, MAPELLI P, INCERTI E, et. al. Evaluation of prostate cancer with 11C-choline PET/CT for treatment planning, response assessment, and prognosis. J Nucl Med 2016; 57: 49S-54S.
[14]. KOPKA K, BENESOVA M, BARINKA C, HABERKORN U, et. al. Glu-Ureido–based inhibitors of prostate-specific membrane antigen: lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers. J Nucl Med. 2017; 58: 17S-26S.
[15]. RAHBAR K, AFSHAR-OROMIEH A, JADVAR H, AHMADZADEHFAR H. PSMA theranostics: current status and future directions. Mol Imaging. 2018; 17: 1-9. doi: 10.1177/1536012118776068
[16]. GOURNI E, HENRIKSEN G. Metal-Based PSMA radioligands. Molecules. 2017; 22: 523. doi:10.3390/molecules22040523
[17]. EVANS JC, MALHOTRA M, CRYAN JF, O’DRISCOLL CM. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. British J Pharm. 2016; 173: 3041-3079.
[18]. BOSCHI A, UCCELLI L, MARTINI P. A picture of modern Tc-99m radiopharmaceuticals: production, chemistry, and applications in molecular imaging. Appl Sci. 2019; 9, 2526. doi: 10.3390/app9122526.
[19]. PANDIT-TASKAR N, VEACH DR, FOX JJ, SCHER HI, et. al. Evaluation of castration-resistant prostate cancer with androgen receptor-axis imaging. J Nucl Med. 2016; 57: 73S-78S.
[20]. WU M, SHU J. Multimodal molecular imaging: current status and future directions. Contrast Media Mol Imaging. 2018: 1382183. doi: 10.1155/2018/1382183.
[21]. OLIVA GONZÁLEZ JP, MARTÍNEZ RAMÍREZ A. Baum RP. Aplicaciones del PET/CT en oncología. Nucleus. 2017; (62): 10-12.
[22]. IAEA. Cyclotron produced radionuclides: physical characteristics and production methods. Technical Reports Series No. 468. Vienna: IAEA, 2009.
[23]. VIRGOLINI I, DECRISTOFORO C, HAUG A, FANTI S, et. al. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018; 45: 471-495.
[24]. CZARNIECKI M, MENA E, LINDENBERG L, CACKO M, et. al. Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents. Transl Androl Urol. 2018; 7(5): 831-843.
[25]. KLEIN NULENT TJW, van ES RJJ, KRIJGER GC, de BREE R, et. al. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma - a preliminary analysis. Eur J Nucl Med Mol Imaging. 2017; 44: 1614-1621.
[26]. GOURNI E, DEL POZZO L, BARTHOLOMA M, KIEFER Y, et. al. Radiochemistry and preclinical pet imaging of 68Ga-desferrioxamine radiotracers targeting prostate-specific membrane antigen. Mol Imaging. 2017; 16: 1-11. doi: 10.1177/1536012117737010
[27]. FENDLER WP, EIBER M, BEHESHTI M, BOMANJI J, et. al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017. doi 10.1007/s00259-017-3670-z
[28]. YOUNG JD, ABBATE V, IMBERTI C, MESZAROS LK, et. al. 68Ga-THP-PSMA: a PET imaging agent for prostate cancer offering rapid, room temperature, one-step kit-based radiolabeling. J Nucl Med. 2017; 58: 1270–1277.
[29]. PASTORINO S, RIONDATO M, UCCELLI L, GIOVACCHINI G, et. al. Toward the discovery and development of PSMA targeted inhibitors for nuclear medicine applications. Curr Radiopharm. 2020; 13: 63-79.
[30]. GIESEL FL, KNORR K, SPOHN F, WILL L, et. al. Detection efficacy of 18F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med. 2019; 60: 362-368.
[31]. CLEEREN F, LECINANJ, BILLAUD EMF, AHAMED M, et. al. New chelators for low temperature Al18F‑labeling of biomolecules. Bioconjugate Chem. 2016; 27; 790-798.
[32]. GIGLIO J, ZENI M, SAVIO E, ENGLER H. Synthesis of an Al18F radiofluorinated GLUUREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform. EJNMMI Radiopharm Chem. 2018; 3: 4. doi: 10.1186/s41181-018-0039-y.
[33]. HASSAN H, RAZAK HRA, SAAD FFA, KUMAR V. 18F[AlF]-radiolabelled peptides on the automated synthesis platform: translating the laboratory bench work to bedside. Malays J Med Sci. 2019; 26: 122-126.
[34]. CUI C, HANYU M, HATORI A, ZHANG Y, et. al. Synthesis and evaluation of [64Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer. Am J Nucl Med Mol Imaging. 2017; 7: 40-52.
[35]. MÜLLER C, DOMNANICH KA, UMBRICHT CA, van der MEULEN NP. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application. Br J Radiol. 2018; 91: 20180074.
[36]. PEDERSEN KS, BAUN C, NIELSEN KM, THISGAARD H, et. al. Design, synthesis, computational, and preclinical evaluation of natTi/45Ti-labeled urea-based glutamate PSMA ligand. Molecules 2020; 25: 1104. DOI:10.3390/molecules25051104
[37]. PERERA PINTADO A, TORRES AROCHE LA, VERGARA GIL A, BATISTA CUÉLLAR JF, et. al. SPECT/CT: principales aplicaciones en la medicina nuclear. Nucleus. 2017; (62): 2-9.
[38]. BARRETT JA, COLEMAN E, GOLDSMITH SJ, VALLABHAJOSULA S, et. al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013; 54: 380-387.
[39]. BANERJEE RS, PULLAMBHATLA M, FOSS CA, FALK A, et. al. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). J Med Chem. 2013; 56: 6108-6121.
[40]. FERRO-FLORES G, LUNA-GUTIÉRREZ M, OCAMPO-GARCÍA B, et al. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT. Nucl Med Biol. 2017; 48: 36-44.
[41]. XU X, ZHANG J, HU S, et. al. 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen. Nucl Med Biol. 2017; 48: 69-75.
[42]. ROBU S, SCHOTTELIUS M, EIBER M, et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med. 2017; 58: 235-242.
[43]. HENDRIKX JJMA. Automated synthesis and quality control of [99mTc]Tc-PSMA for radioguided surgery (in a [68Ga]Ga-PSMA workflow). EJNMMI Radiopharm Chem 2020; 5: 10. doi: 10.1186/s41181-020-00095-9.
[44]. WERNER P, NEUMANN C, EIBER M, WESTER HJ, SCHOTTELIUS M. [99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. EJNMMI Res. 2020; 10: 45. doi: 10.1186/s13550-020-00635-z.
[45]. VATS K, AGRAWAL K, SHARMA R, SARMA HD, SATPATI D, DASHAD A. Preparation and clinical translation of 99mTc-PSMA-11 for SPECT imaging of prostate cancer. Med Chem Commun. 2019; 10: 2111-2117.